Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00083993 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer
A Phase 3 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,236
- Enrollment target
NCT00083993: Clinical Trial Phase 3 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
NCT00083993 is a Phase 3 study that was terminated before completion, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 1,236 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (60% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00083993, a Phase 3 study, was terminated before completion, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,236 participants
- Enrollment target
Study Summary
In this clinical research study, postmenopausal subjects with metastatic breast cancer will be given either the combination of temsirolimus (CCI-779) and letrozole or a placebo and letrozole in first-line hormonal treatment. The primary endpoint of this study is to determine overall progression free survival. Individual subjects will participate in the active treatment phase of the study until disease progression or withdrawal of consent, provided that test article is being tolerated. All subjects will be asked to participate in the long-term follow-up phase of the study, which includes follow-up every 3 months until disease progression (for subjects who withdraw for reasons other than documented progressive disease) or until any new cancer treatment is received, and for survival. The estimated duration of study participation is 34 months.
Interventions
- DRUG Temsirolimus (CCI-779) for 34 months
- DRUG Letrozole for 34 months
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,236 participants |
| Start Date | 2004-05 |
| Est. Completion | 2006-10 |
| Phase | Phase 3 |
Why NCT00083993 stopped before completion
NCT00083993 is an interventional study that assigns participants to a tested intervention. Its 1,236 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (60% higher).
The record links to 0 conditions, and to 2 interventions - of which Temsirolimus (CCI-779) for 34 months is the first listed.
NCT00083993 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00083993 about?
NCT00083993 is a clinical study titled "Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer". In this clinical research study, postmenopausal subjects with metastatic breast cancer will be given either the combination of temsirolimus (CCI-779) and letrozole or a placebo and letrozole in first-line hormonal treatment. The primary endpoint of this study is to determine overall progression free...
What is the current status of trial NCT00083993?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,236 participants. The study started on 2004-05. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00083993?
The interventions under investigation include: Temsirolimus (CCI-779) for 34 months (DRUG), Letrozole for 34 months (DRUG).
Who is sponsoring clinical trial NCT00083993?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00083993's enrollment target sits among peer trials
1,236 214th of 2000 higher than 1,787 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05456841 · 1,232 participants · NA
Empathic Communication Skills (ECS) Training
- NCT05946044 · 1,230 participants · NA
The Osteoarthritis Prevention Study
- NCT06787937 · 1,230 participants · NA
Communicating About Nicotine Reduction in Cigarettes
- NCT06368245 · 1,244 participants
Durability of Suppl. Rod Constructs-SuppleMentAry Rod Technique for Long-segment Posterior Instrumented Spinal Fusions
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia